Clinical trials: Malignant Melanoma
Melanoma
18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 18F labeled Picolinamide (18F-P3BZA) and preliminarily evaluate its diagnosis value in melanoma patients.
- Trial name
- NCT03033485
- Testing
- 18F-P3BZA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xijing Hospital
Melanoma
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
The purpose of this study is to learn the effects an experimental vaccine (MELITAC 12.1) combined with other substances called lipopolysaccharide (LPS; endotoxin), polyICLC, and Montanide ISA-51.
- Trial name
- MEL58 (NCT01585350)
- Testing
- MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Craig L Slingluff, Jr
Uveal Melanoma, Metastatic
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
- Trial name
- TRIUMPH (NCT07203391)
- Testing
- roginolisib
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- St Vincent's Hospital, Sydney
Malignant Melanoma
GM-CSF as Adjuvant Therapy of Melanoma
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in…
- Trial name
- NCT00350597
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northern California Melanoma Center
Melanoma (Skin Cancer), Artificial Intelligence (AI)
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30).
- Conditions
- Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer
- Trial name
- AI-MEL (NCT06621810)
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- German Cancer Research Center
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Recurrent Melanoma, Stage IV Melanoma
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
SU5416 may stop the growth of malignant melanoma by stopping blood flow to the tumor. Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic melanoma that has been previously treated
- Trial name
- NCT00006003
- Testing
- semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
NSCLC, Ovarian Cancer
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
- Conditions
- NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
- Trial name
- NCT02607813
- Testing
- LXH254, PDR001
- Where
- 18 sites in United States, Canada and 8 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in…
- Trial name
- NCT03068624
- Testing
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Metastasis From Malignant Melanoma of Skin (Diagnosis)
Irradiation of Melanoma in a Pulse
This is a single center phase I, first-in-human, dose escalation study of FLASH therapy in patients with metastases of melanoma.
- Trial name
- IMPulse (NCT04986696)
- Testing
- FLASH therapy
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Recurrence of Solid Tumor, Glioblastoma Multiforme
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
This is a non-randomized two-part study of MK-4827 given with temozolomide in participants with advanced cancer. In Part A of the study, the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of MK-4827 when…
- Conditions
- Recurrence of Solid Tumor, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT01294735
- Testing
- MK-4827, Temozolomide
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Breast Neoplasms
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors.
- Conditions
- Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer
- Trial name
- NCT00600496
- Testing
- AZD6244, Dacarbazine, Erlotinib
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Tumor Infiltrating Lymphocytes, Safety
A Study of GC101 TIL in Advanced Melanoma (BZ)
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy
- Trial name
- MIZAR-002 (NCT06120712)
- Testing
- GC101 TIL
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Metastatic Melanoma
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.
- Trial name
- NCT00984464
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Metastatic Melanoma
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat.
- Trial name
- NCT00925132
- Testing
- Temozolomide, Decitabine, Panobinostat
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Stage IV Skin Melanoma
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.
- Trial name
- BRAFV600 (NCT01960634)
- Where
- 13 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Melanoma
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
- Trial name
- NCT01009775
- Testing
- YM155, Docetaxel
- Where
- 13 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.